James E Herndon

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials
    James E Herndon
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
    Psychooncology 22:315-23. 2013
  2. pmc Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC, USA
    BMC Cancer 10:531. 2010
  3. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008
  4. pmc Patient education level as a predictor of survival in lung cancer clinical trials
    James E Herndon
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4116-23. 2008
  5. pmc Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:4759-67. 2012
  6. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
  7. ncbi request reprint Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 103:329-38. 2005
  8. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
  9. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
  10. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008

Research Grants

  1. ACOSOG STATISTICS AND DATA COORDINATING CENTER
    James Herndon; Fiscal Year: 2004

Detail Information

Publications120 found, 100 shown here

  1. doi request reprint Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials
    James E Herndon
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
    Psychooncology 22:315-23. 2013
    ..This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B...
  2. pmc Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC, USA
    BMC Cancer 10:531. 2010
    ....
  3. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008
    ..The objective of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis...
  4. pmc Patient education level as a predictor of survival in lung cancer clinical trials
    James E Herndon
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4116-23. 2008
    ..To investigate the effect of socioeconomic status, as measured by education, on the survival of 1,577 lung cancer patients treated on 11 studies conducted by the Cancer and Leukemia Group B...
  5. pmc Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:4759-67. 2012
    ..We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma...
  6. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  7. ncbi request reprint Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 103:329-38. 2005
    ..In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease...
  8. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  9. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  10. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  11. pmc Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2188-98. 2009
    ....
  12. doi request reprint Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
    James J Vredenburgh
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 82:58-66. 2012
    ..To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)...
  13. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  14. pmc Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
    ..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...
  15. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  16. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  17. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  18. doi request reprint Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  19. pmc The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma
    James J Vredenburgh
    Departments of Surgery, Neurology, Pediatrics, Medicine, Radiation Oncology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina
    Clin Cancer Res 17:4119-24. 2011
    ..To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective...
  20. pmc Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neuro Oncol 13:324-33. 2011
    ..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity...
  21. pmc Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
    Emil Lou
    Preston Robert Tisch Brain Tumor Center at Duke, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer Med 2:185-95. 2013
    ..The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials...
  22. pmc Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 10:330-40. 2008
    ..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population...
  23. pmc Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:145-53. 2004
    ....
  24. doi request reprint Bevacizumab and daily temozolomide for recurrent glioblastoma
    Annick Desjardins
    Department of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 118:1302-12. 2012
    ..The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide...
  25. pmc Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma
    Emily Ruden
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 29:2918-23. 2011
    ..We investigated the prognostic significance of exercise behavior and functional capacity in this population...
  26. pmc Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 117:5351-8. 2011
    ..The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated...
  27. pmc Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
    David A Reardon
    Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 106:409-15. 2012
    ..The only grade 3 or greater adverse event occurring in ≥ 10% of patients was anemia (10%). Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication...
  28. doi request reprint Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    ..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated...
  29. pmc Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 107:155-64. 2012
    ..ClinicalTrials.gov number NCT00953121)...
  30. doi request reprint A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
    Annick Desjardins
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 105:601-6. 2011
    ..No grade 4 or 5 toxicities were observed. The phase II dose of SCH 66336 when combined with temozolomide is 150 mg twice daily for patients not on EIAEDs and 175 mg twice daily for patients on EIAEDs...
  31. pmc Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    J Neurooncol 105:621-7. 2011
    ..The combination of sunitinib and irinotecan was associated with moderate toxicity and limited anti-tumor activity. Further studies with this regimen using the dosing schedules evaluated in this study are not warranted...
  32. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  33. pmc Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 103:371-9. 2011
    ..Alternative treatment strategies remain critically needed for this indication...
  34. pmc Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  35. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
    ..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma...
  36. pmc Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:405-13. 2007
    ....
  37. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  38. pmc Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 12:1300-10. 2010
    ..Bevacizumab plus erlotinib was adequately tolerated in recurrent MG patients. However, this regimen was associated with similar PFS benefit and radiographic response when compared with other historical bevacizumab-containing regimens...
  39. pmc Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Michael A Badruddoja
    Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 9:70-4. 2007
    ..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme...
  40. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  41. doi request reprint Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial
    Alvin R Cabrera
    Department of Radiation Oncology, Duke University, Durham, North Carolina, USA
    Int J Radiat Oncol Biol Phys 86:873-9. 2013
    ..Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG...
  42. pmc Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
    Duane A Mitchell
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
    Blood 118:3003-12. 2011
    ....
  43. ncbi request reprint Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1478-86. 2005
    ..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)...
  44. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  45. pmc Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy
    April K S Salama
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    PLoS ONE 8:e57665. 2013
    ..The objectives of this study were to identify patterns of metastatic recurrence, to determine the influence of metastatic site on survival, and to identify high-risk periods for recurrence...
  46. pmc BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide
    Luis Sanchez-Perez
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Immunol Immunother 62:983-7. 2013
    ..These observations should be considered for the development of future vaccination strategies in the setting of malignancy...
  47. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  48. pmc A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e31046. 2012
    ..However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells...
  49. pmc MRP3: a molecular target for human glioblastoma multiforme immunotherapy
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    BMC Cancer 10:468. 2010
    ..We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3)...
  50. ncbi request reprint A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer
    Richard F Riedel
    Ruth and Herman Albert Thoracic Oncology Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Thorac Oncol 2:520-5. 2007
    ..A phase II study investigating carboplatin and vinorelbine, supported by pegfilgrastim, in the treatment of patients with advanced NSCLC was performed...
  51. pmc Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Support Care Cancer 18:893-8. 2010
    ..This prospective, single-arm, phase 2 pilot study examined the acceptability and feasibility of Pathfinders for women with metastatic breast cancer...
  52. pmc A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Natl Compr Canc Netw 9:414-27. 2011
    ..Better understanding of resistance mechanisms to VEGF inhibitors and identification of effective therapy after bevacizumab progression are currently a critical need for patients with glioblastoma...
  53. doi request reprint Poor drug distribution as a possible explanation for the results of the PRECISE trial
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University, Durham, North Carolina, USA
    J Neurosurg 113:301-9. 2010
    ..The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial...
  54. ncbi request reprint Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection
    Kelli R Brooks
    Thoracic Oncology Program, Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 76:187-93; discussion 193. 2003
    ....
  55. ncbi request reprint Survival analysis of presumptive prognostic markers among oligodendrogliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1693-9. 2005
    ..However, the authors questioned the relevance of genetic testing and measuring MGMT levels in tumors that were diagnostic of oligodendroglioma...
  56. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  57. doi request reprint Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma
    Jenny K Hoang
    Department of Radiology, Duke University Medical Center, Erwin Rd, Durham, NC 27710, USA
    J Clin Oncol 26:1459-64. 2008
    ....
  58. ncbi request reprint Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    Lawrence B Marks
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 22:4329-40. 2004
    ..6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N)...
  59. pmc Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study
    SOPHIA K SMITH
    Duke Comprehensive Cancer Center, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Psychooncology 20:559-64. 2011
    ..This study explores the relationship between psychosocial resources invoked through the Pathfinders intervention and outcomes...
  60. doi request reprint Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pain Symptom Manage 40:545-58. 2010
    ..Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting...
  61. pmc Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions
    John H Sampson
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 9:343-53. 2007
    ..6% of catheters. Routine use of this algorithm, and its further developments, should improve prospective selection of catheter trajectories, and thereby improve the efficacy of drugs delivered by this promising technique...
  62. pmc Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
    Emil Lou
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 109:63-70. 2012
    ..Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted...
  63. pmc Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 39:23-34. 2012
    ..This motivated the generation of MAb D2C7, which recognizes both wild-type epidermal growth factor receptor (EGFRwt) and a tumor-specific mutant, EGFRvIII...
  64. pmc Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer
    Lee W Jones
    Duke Univ Medical Center, Durham, NC 27710, USA
    J Appl Physiol (1985) 108:343-8. 2010
    ..Such findings may have important implications for inhibiting tumor metastasis and improving the efficacy of conventional cancer therapies...
  65. pmc Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Box 3436, Durham, NC 27710, USA
    Health Serv Res 43:1975-91. 2008
    ..DATA/SETTING: Primary/Duke Breast Cancer Clinic...
  66. pmc Temozolomide in children with progressive low-grade glioma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 9:161-8. 2007
    ..TMZ given in this schedule was successful in stabilizing disease in a significant proportion of the patients with OPG/PA, with manageable toxicity...
  67. ncbi request reprint Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence
    Joerg Gauger
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Thorac Oncol 2:499-505. 2007
    ..The purpose of this study was to determine the sites and time to recurrence in patients with clinical stage I NSCLC whose initial staging evaluation included conventional imaging and fluorodeoxyglucose-PET...
  68. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  69. pmc Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321
    Dale Ding
    School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neurol Res 32:810-5. 2010
    ..In this study, we assess the long-term safety and toxicity of intracerebrally infused Gd-DTPA along with an experimental targeted agent PRX321...
  70. ncbi request reprint A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer
    Jennifer Garst
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Drug Investig 26:257-66. 2006
    ....
  71. pmc EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells
    Hidenobu Ochiai
    Department of Surgery Neurosurgery, Duke University Medical Center, Box 3050, Durham, NC, 27710, USA
    Cancer Immunol Immunother 57:115-21. 2008
    ..However, delayed and often dramatic antitumor responses seen in human studies with targeted toxins led us to hypothesize that immunologic responses may be a secondary mechanism that enhances the therapeutic efficacy of these novel drugs...
  72. pmc Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas
    Chien Tsun Kuan
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 129:111-21. 2011
    ..These GPNMB-specific scFv antibodies and immunotoxins hold promise as reagents in targeted therapy for HGGs and other GPNMB-expressing malignancies...
  73. pmc Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum
    Lee W Jones
    Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 30:2530-7. 2012
    ..To evaluate cardiopulmonary function (as measured by peak oxygen consumption [VO(2peak)]) across the breast cancer continuum and its prognostic significance in women with metastatic disease...
  74. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
    ..These data, obtained from a usual-practice setting, provide benchmarks to improve clinical practice...
  75. ncbi request reprint Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury
    Mitchell S Anscher
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 66:477-82. 2006
    ..The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelbine plus thoracic radiotherapy...
  76. ncbi request reprint Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme
    Chien Tsun Kuan
    Preston Robert Tisch Brain Tumor Center at Duke, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 12:1970-82. 2006
    ....
  77. ncbi request reprint Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Mol Cancer Ther 5:2531-9. 2006
    ..The data also suggest that consideration be given to the large population of AGT-expressing cells within samples when therapeutic strategies based on tumor methylation are used...
  78. ncbi request reprint Panel of serum biomarkers for the diagnosis of lung cancer
    Edward F Patz
    Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA
    J Clin Oncol 25:5578-83. 2007
    ..Serum biomarkers that could aid clinicians in making case management decisions would be enormously valuable. We used two proteomic platforms and a literature search to select candidate serum markers for the diagnosis of lung cancer...
  79. ncbi request reprint Use of tablet personal computers for sensitive patient-reported information
    Alexandra Dupont
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Support Oncol 7:91-7. 2009
    ..The e/Tablet electronic system may provide a "safer" environment than paper questionnaires for cancer patients to answer private or highly personal questions on sensitive topics such as sexuality...
  80. ncbi request reprint Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer
    Sendhil Kumar Cheran
    School of Medicine, Duke University, Durham, NC 27710, USA
    Lung Cancer 44:317-25. 2004
    ..A prospective trial with appropriate verification of bony metastases is suggested to confirm the results...
  81. ncbi request reprint Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy
    Mitchell S Anscher
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 56:988-95. 2003
    ..To report the incidence of late complications in long-term survivors of very-high-dose thoracic radiotherapy (RT) treated on a prospective clinical trial...
  82. pmc Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:134-44. 2004
    ..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic...
  83. ncbi request reprint Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant b
    John H Sampson
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 65:27-35. 2003
    ..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks...
  84. ncbi request reprint Molecular markers of prognosis in astrocytic tumors
    Ahmed Rasheed
    Department of Pathology, Duke University Medical Center, 3156, Durham, NC 27710, USA
    Cancer 94:2688-97. 2002
    ..To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective standards against which to establish diagnosis and grade...
  85. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  86. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  87. pmc Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
    Lancet 376:784-93. 2010
    ..We assessed the effectiveness of oxygen compared with room air delivered by nasal cannula for relief of breathlessness in this population of patients...
  88. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  89. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  90. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  91. doi request reprint Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center DUMC, Box 3436, Durham, NC 27710, USA
    Support Care Cancer 17:735-44. 2009
    ..How frequently does care at our institution conform to established guidelines?..
  92. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  93. ncbi request reprint [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma
    Sridharan Gururangan
    The Brain Tumor Center at Duke, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Neurosurgery 55:1280-8; discussion 1288-9. 2004
    ..We evaluated the [(18)F]fluorodeoxyglucose (FDG) accumulation during positron emission tomography (PET) in patients with medulloblastoma and examined the relationship of intensity of uptake with patient outcome after the initial scan...
  94. ncbi request reprint Safety and efficacy of weekly oral oltipraz in chronic smokers
    Michael J Kelley
    Department of Medicine, Duke University and Durham Veterans Affairs Hospital, Hematology Oncology 111G, 508 Fulton Street, Durham, NC 27705, USA
    Cancer Epidemiol Biomarkers Prev 14:892-9. 2005
    ..Other agents with lower toxicity and greater activity to induce phase II enzymes are needed to definitively test the detoxification-induction paradigm in smokers...
  95. ncbi request reprint Phase II study of carboplatin in children with progressive low-grade gliomas
    Sridharan Gururangan
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2951-8. 2002
    ..To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas...
  96. ncbi request reprint T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET
    Edith M Marom
    Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA
    Radiology 223:453-9. 2002
    ..To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (< or =3 cm) lung cancers...
  97. doi request reprint Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
    Robert J Schmittling
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol Methods 339:74-81. 2008
    ..Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH...
  98. doi request reprint Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology
    Amy P Abernethy
    Division of Medical Oncology, Center for Clinical Health Policy Research, Duke University Medical Center, Box 3436, 1 Trent Drive, Durham, NC 27710 USA
    J Pain Symptom Manage 37:1027-38. 2009
    ..E/Tablets offered a feasible and acceptable method for collecting longitudinal patient-reported symptom and QOL data within an academic, tertiary care, breast cancer clinic...
  99. ncbi request reprint Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B
    Everett E Vokes
    University of Chicago, Chicago, IL, USA
    J Clin Oncol 25:1698-704. 2007
    ..In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival...
  100. ncbi request reprint Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 20:686-92. 2002
    ..45%) (p = 0.042). A trend toward longer median survivals was seen in patients with positive p53 staining. This study does not support the ability of p53 staining to predict chemotherapy resistance...
  101. ncbi request reprint Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B
    Wallace Akerley
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84103, USA
    Cancer 97:2480-6. 2003
    ....

Research Grants1

  1. ACOSOG STATISTICS AND DATA COORDINATING CENTER
    James Herndon; Fiscal Year: 2004
    ..abstract_text> ..